摘要
目的观察贝伐珠单抗联合FOLFIRI方案治疗晚期结直肠癌的近期疗效和不良反应。方法选取28例经组织病理学证实的晚期结肠癌患者,使用贝伐珠单抗联合FOLFIRI方案治疗。FOLFIRI方案,第1天伊立替康注射液180 mg/m2静脉滴注,第1,2天亚叶酸钙注射液200 mg/m2静脉滴注2 h,第1,2天氟尿嘧啶注射液400 mg/m2静脉推注射;第1,2天600 mg/m2持续静脉输注22 h。2周重复用药。化疗后第2天使用贝伐珠单抗,用量5 mg/kg,每2周为1个周期,每3周期评价疗效。结果 28例患者中无完全缓解病例,部分缓解7例(25.00%),疾病稳定13例(46.43%),总有效率(RR)25.00%,疾病控制率(DCR)71.43%;不良反应主要为骨髓抑制,恶心呕吐、腹泻、高血压、蛋白尿,经过对症处理后好转,无治疗相关死亡。结论贝伐珠单抗联合FOLFIRI方案治疗晚期结直肠癌疗效确切,疾病控制率高,不良反应无明显加重,患者耐受性好,值得临床推广。
Objective To observe the efficacy and adverse effects of Bevacizumab combined with FOLFOIRI regimen in the treatment of advanced colorectal cancer. Methods Use Bevacizumab combined with FOLFIRI regimen to treat 28 cases of patients with advanced colon cancer confirmed by histopathology. FOLFIRI program： irinotecan 180 mg / m2 for one day intravenously, leucovorin injection （CF） 200 mg / m2 for 2 h intravenously, day 1 - 2, 5 - Fu 400 mg / m2 bolus day 1 - 2; 600 mg / m2 continuous intravenous infusion for 22 h, day 1 - 2. 2 weeks repeated administration, using Bevacizumab day after chemotherapy, dosage 5 mg / kg, every 2 weeks for a period. The efficacy was evaluated every 3 weeks. Results 28 patients, CR0, PR7 patients （25. 00% ）, SD13 cases （46. 43% ）, total effective rate （RR） 25. 00% , disease control rate （DCR） 71. 43% . The adverse reactions were myelosuppression, nausea and vomiting, diarrhea, hypertension, proteinuria, improved after symptomatic treatment, no treatment - related deaths. Conclusion Bevacizumab combined with FOLFIRI chemotherapy treatment of advanced colorectal cancer curative effect, high disease control rates, no obvious increase adverse re-actions, patients with good tolerance.
出处
《中国药业》
CAS
2015年第15期72-73,共2页
China Pharmaceuticals
